Goldman Sachs Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $34

Goldman Sachs analyst Corinne Johnson maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price target from $28 to $34.